U

Universitätsklinikum Ulm | Innere Medizin III

Research site
(Unclaimed)
Location
Albert-Einstein-Allee 23, Ulm, Baden-Württemberg, Germany
Site insights

Top conditions

Leukemia (32 trials)

Myeloid Leukemia (20 trials)

Acute Myeloid Leukemia (19 trials)

Lymphoma (16 trials)

Lymphoid Leukemia (14 trials)

Top treatments

Carboplatin
Lenalidomide
Paclitaxel
Obinutuzumab
Cytarabine
Idarubicin
Abemaciclib
Empagliflozin
Azacitidine
Gemcitabine

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

78 of 279
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy (PREDICT)

Second-line therapy with Nal-IRI after failure gemcitabine/nab-paclitaxel in advanced pancreatic cancer - predictive role of 1st-line therapy

Active, not recruiting
Locally Advanced Pancreatic Cancer
Metastatic Pancreatic Cancer
Drug: Irinotecan Liposomal Injection [Onivyde]

This study will evaluate the safety, tolerability, and preliminary antitumor activity of CAN04 both as a monotherapy and in combination with standard...

Active, not recruiting
Pancreatic Ductal Adenocarcinoma
Non Small Cell Lung Cancer
Drug: Pemetrexed
Drug: Gemcitabine

A phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 in participants with Early Alzheimer's Disea...

Active, not recruiting
Alzheimer Disease
Drug: Placebo
Drug: AL002

A phase 3 double blind, placebo controlled study evaluating the efficacy and safety of AL001 in participants at risk for or with frontotemporal demen...

Active, not recruiting
Frontotemporal Dementia
Drug: Open label - AL001
Drug: AL001

A Phase Ib/II multicentre open label study of bemcentinib (BGB324) as a single agent in participants with Acute Myeloid Leukemia (AML) or Myelodyspla...

Active, not recruiting
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Drug: Cytarabine
Drug: Decitabine

This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulati...

Enrolling
Colorectal Cancer Stage III
Colorectal Cancer Stage II
Other: Observational group (no intervention)
Drug: RO7198457 intravenous (i.v.)

The Alternative-C Trial is a prospective, multicenter Phase 2 Study to evaluate the efficacy of the chemotherapy-free combination of copanlisib and o...

Active, not recruiting
Follicular Lymphoma
Drug: Obinutuzumab
Drug: Copanlisib

The purpose of the study is to evaluate the efficacy, safety and tolerability and of BGB-3111 plus obinutuzumab versus obinutuzumab alone in particip...

Active, not recruiting
Relapsed/Refractory Follicular Non-Hodgkin Lymphoma
Drug: Obinutuzumab
Drug: Zanubrutinib

The primary objective of this study is to determine the safety and tolerability of multiple doses of QRL-201 in people living with ALS

Enrolling
Amyotrophic Lateral Sclerosis
Drug: QRL-201 - Dose 2
Drug: QRL-201 - Dose 5

This is a single-arm, open-label study to assess the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of tocilizumab (TCZ) for th...

Enrolling
COVID-19
Drug: Tocilizumab

This study has 2 parts. The first part of the study is done. The first part was open to adults with different types of advanced cancer (solid tumors)...

Enrolling
Neoplasms
Drug: BI 907828
Drug: ezabenlimab

The main purpose of this study is to measure how well abemaciclib works in participants with early breast cancer who are taking hormone therapy after...

Active, not recruiting
Breast Neoplasms
Drug: Placebo
Drug: Abemaciclib
Locations recently updated

The main purpose of this study is to evaluate the safety and efficacy of abemaciclib plus tamoxifen or abemaciclib alone in women with previously tre...

Active, not recruiting
Metastatic Breast Cancer
Drug: Tamoxifen
Drug: Abemaciclib

The purpose of this study is to determine the recommended Phase 2 dose regimen or the maximum tolerated dose of JNJ-67856633 in participants with rel...

Active, not recruiting
Lymphoma, Non-Hodgkin
Leukemia, Lymphocytic, Chronic, B-Cell
Drug: JNJ-67856633

The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of JNJ-75276617 in combination with AML directed therapies...

Enrolling
Leukemia, Myeloid, Acute
Drug: Azacitidine (AZA)
Drug: Cytarabine

The primary purpose of this study is to compare the efficacy of the study drug LY2875358, given together with erlotinib, against erlotinib, alone. Pa...

Active, not recruiting
Carcinoma, Non-Small-Cell Lung
Biological: LY2875358
Drug: Erlotinib
Locations recently updated

The purpose of this study is to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in participants with symptomatic...

Enrolling
Cardiomyopathy, Hypertrophic
Drug: Mavacamten
Other: Placebo

The purpose of this study is to evaluate the efficacy and safety of nipocalimab compared to placebo in participants with generalized myasthenia gravi...

Enrolling
Myasthenia Gravis
Drug: Placebo
Drug: Nipocalimab

The main purpose of this study is to evaluate how effective nonsteroidal aromatase inhibitors (NSAI) plus abemaciclib are in postmenopausal women wit...

Active, not recruiting
Breast Cancer
Drug: Letrozole
Drug: Placebo

The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants...

Enrolling
Leukemia, B-cell
Small Lymphocytic Lymphoma
Drug: Pirtobrutinib
Drug: Ibrutinib

Trial sponsors

Boehringer Ingelheim logo

Boehringer Ingelheim (28 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems